Imaging of prostate cancer presents many challenges to the imaging community. There has been much progress in this space in large part due to MRI and PET radiopharmaceuticals. Though MRI has been focused on the evaluation of local disease and PET on the detection of metastatic disease, these two areas do converge and will be complementary especially with the growth of new PET/MRI technologies.
In this review article, we review novel MRI, MRI/US, and PET radiopharmaceuticals which will offer insight into the future direction of imaging in prostate cancer.
Current oncology reports. 2015 Dec [Epub]
Phillip J Koo, Jennifer J Kwak, Sajal Pokharel, Peter L Choyke
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA. Division of Abdominal Imaging, Department of Radiology, University of Colorado School of Medicine, Mail Stop L954, 12401 E. 17th Avenue, Room 1512, Aurora, CO, 80045, USA. Center for Cancer Research, National Cancer Institute, Building 10, Room B3B69F, Bethesda, MD, 20892-1088, USA.